P.1.041 Growth hormone response to L-DOPA and dexamethasone suppression tests before and after treatment in depressive patients

2003 ◽  
Vol 13 ◽  
pp. S191-S192
Author(s):  
E. Esel ◽  
S. Kartalci ◽  
M. Kula ◽  
M.T. Turan ◽  
Y. Hacimusalar ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Response ◽  
Hormone Response ◽  
Before And After ◽  
Depressive Patients ◽  
Dexamethasone Suppression

Growth hormone response to clonidine and the cortisol response to dexamethasone in depressive patients

1996 ◽  
Vol 60 (1) ◽  
pp. 23-32 ◽  
Author(s):  
Sergio Valdivieso ◽  
Fabrice Duval ◽  
Marie-Claude Mokrani ◽  
Nicolas Schaltenbrand ◽  
Juarez Oliveira Castro ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Response ◽  
Cortisol Response ◽  
Hormone Response ◽  
Depressive Patients

Growth hormone response to D-amphetamine in normal controls and in depressive patients

1975 ◽  
Vol 1 (3) ◽  
pp. 185-189 ◽  
Author(s):  
Gerhard Langer ◽  
Gerhard Heinze ◽  
Beatrix Reim ◽  
Norbert Matussek
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Response ◽  
Hormone Response ◽  
Depressive Patients ◽  
Normal Controls

scholarly journals Decreased sensitivity of 5-HT1D receptors in melancholic depression

2001 ◽  
Vol 178 (5) ◽  
pp. 454-457 ◽  
Author(s):  
Richard Whale ◽  
Elizabeth M. Clifford ◽  
Zubin Bhagwagar ◽  
Philip J. Cowen
Keyword(s):  
Growth Hormone ◽  
Major Depression ◽  
Growth Hormone Response ◽  
Receptor Subtypes ◽  
Hormone Release ◽  
Growth Hormone Release ◽  
Hormone Response ◽  
Melancholic Depression ◽  
Before And After ◽  
Ssri Treatment

BackgroundBrain serotonin (5-HT) function is abnormal in major depression, but the involvement of different 5-HT receptor subtypes has been little studied. The availability of selective ligands now makes it possible to test the sensitivity of 5-HT1D receptors in patients with depression.AimsThe aim of the study was to use the 5-HT1D receptor agonist, zolmitriptan, to test the sensitivity of 5-HT1D receptors in patients with depression before and after treatment with selective serotonin reuptake inhibitors (SSRIs).MethodWe measured the growth hormone response to zolmitriptan (5 mg orally) in patients with major depression before and after SSRI treatment. A matched sample of healthy subjects acted as a control group.ResultsThe growth hormone response to zolmitriptan was blunted in patients with a melancholic depressive syndrome. SSRI treatment produced a marked reduction in zolmitriptan-induced growth hormone release.ConclusionsPatients with melancholic depression have impaired sensitivity of the post-synaptic 5-HT1D receptors that mediate growth hormone release. The reduction in 5-HT1D receptor sensitivity following SSRI treatment is probably an adaptive response to increased levels of synaptic 5-HT.

Sign in / Sign up

Export Citation Format

Share Document